Russian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Страница 1 от 18 полученные результаты
Safety Assessment of P2Et Extract in Healthy Voluntary Subjects in Colombia
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
The P2Et extract will be self-administered by the participants on a daily basis (600 mg 1 daily capsule, 2 daily capsules for 1,200 mg, 4 daily capsules for 2,400 and 8 daily capsules for 4,800 mg) 1 hour after meals and at the same time every day, from day 1 to day 30.
In the event that the
Prevention of Phototoxicities in Patients Undergoing Vemurafenib Treatment
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Vemurafenib is an anti-cancer treatment indicated as monotherapy in the treatment of adult patients with non-resectable or metastatic melanoma carrying a BRAF V600 mutation.
Cobimetinib is indicated in combination with Vemurafenib in the treatment of adult patients with non-resectable or metastatic
Comparison of Cost-effectiveness of Continuation Maintenance Therapy With Six Cycles of Pemetrexed Versus Pemetrexed Until Disease Progression for Metastatic Non-squamous Non-small-cell Lung Cancer
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Inclusion criteria:
1. Males and females ≥ 20 years of age
2. ECOG performance status of 0-1
3. Histologically or cytologically verified non-squamous NSCLC
4. Stage IV disease, as defined by American Joint Committee on Cancer 7th edition staging, prior to first-line or second-line chemotherapy with
Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic GVHD
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
This research study is a Phase I clinical trial, which tests the safety of an investigational intervention and also tries to define the appropriate dose of the investigational intervention to use for further studies. "Investigational" means that the intervention is being studied.
The FDA (the U.S.
Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
This is a Phase 2B double-blind placebo-controlled crossover study evaluating the efficacy of intravenous fosaprepitant for chemotherapy-induced nausea and vomiting in patients undergoing high-dose interleukin-2 (HD IL-2) therapy (720,000 IU/kg per dose intravenously; 14 doses, 2 cycles per course)
A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Rationale for treatment of uveal melanoma with sorafenib Improved understanding of the molecular pathogenesis of cancers has led to a new generation of therapeutic agents that interfere with a specific pathway critical in tumor development or progression. Although no specific genes have been linked
Effects of Anesthetic Technique on Immune and Inflammatory Systems Following Radical Prostatectomy
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Methods
Thirty patients (ASA status 1-2) in the age group 50 - 75 years, undergoing elective radical retropubic prostatectomy would be included in this pilot study. The exact type of cancer, its staging, degree of spread to proximal or distant sites and the pathologic type of cancer would be
Open-Label Study of TPI 287 for Patients With Metastatic Melanoma
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
The Study Drug TPI 287 is designed to block tumors from growing by preventing cancer cells from dividing, which may cause them to die.
Study Groups:
Patient will be assigned to a study group based on when they join this study. Up to 4 groups of 3-6 participants will be enrolled in the Phase I
177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
(177)Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms
First Annual Report on protocol IND# 78,256 at RITA Foundation in collaboration with Excel diagnostics and Nuclear Oncology center and Baylor College of Medicine
Protocol number 78,256 calls for
Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Study Drugs:
Oblimersen is designed to stop the body from making a protein that makes melanoma cells resistant to chemotherapy drugs. This may make carboplatin and/or paclitaxel more effective.
Carboplatin is designed to interfere with the growth of cancer cells by stopping cell division, which may
Ipilimumab + Temozolomide in Metastatic Melanoma
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
The ability to control melanoma depends on how well your immune system recognizes and then attacks cancer cells. Researchers want to use ipilimumab to try to trigger your immune system response, while temozolomide is designed to damage the cancer cells themselves.
Study Drugs:
Ipilimumab is designed
A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Study Drugs:
TPI 287 is designed to block tumors from growing by preventing cancer cells from dividing.
Temozolomide is designed to kill cancer cells by causing breaks in the DNA (genetic material) of the cell.
Study Groups:
If you are found to be eligible to take part in this study, you will be
Phase II Study of Tesetaxel in Metastatic Melanoma
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
The Study Drug:
Tesetaxel is designed to block cancer cells from dividing, which may cause them to die.
Study Groups:
If you are found to be eligible to take part in this study, you will be assigned to 1 of 2 Groups based on when you enroll in this study. Each group has 2 "stages."
Group A:
A total
Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
The Study Drug:
Nab-paclitaxel is designed to block cancer cells from dividing, which may cause them to die.
Study Drug Groups:
If you are found to be eligible to take part in this study, you will be assigned to a dose level of nab-paclitaxel based on when you joined this study. Up to 4 dose levels
Safety Study of CADI-05 in Patients With Advanced Stage Melanoma
Только зарегистрированные пользователи могут переводить статьи
Войти Зарегистрироваться
Because there are no highly effective treatment options for patients with advanced, unresectable melanoma, participation in clinical trials of novel therapies is frequently the best therapeutic alternative. CADI-05 is a promising agent for two reasons. First, patients with advanced melanoma
Самая полная база данных о лекарственных травах, подтвержденная наукой
- Работает на 55 языках
- Травяные лекарства, подтвержденные наукой
- Распознавание трав по изображению
- Интерактивная карта GPS - отметьте травы на месте (скоро)
- Прочтите научные публикации, связанные с вашим поиском
- Ищите лекарственные травы по их действию
- Организуйте свои интересы и будьте в курсе новостей исследований, клинических испытаний и патентов
Введите симптом или заболевание и прочтите о травах, которые могут помочь, введите лекарство и узнайте о болезнях и симптомах, против которых оно применяется.
* Вся информация основана на опубликованных научных исследованиях.
